Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda

Joseph Sempa, Mark Ssennono, Andreas Kuznik, Mohammed Lamorde, Stefanie Sowinski, Aggrey Semeere, Sabine Hermans, Barbara Castelnuovo, Yukari C Manabe

Research output: Contribution to journalArticle

Abstract

Background: Ugandan national guidelines recommend initiation of combination antiretroviral therapy (cART) at CD4 + T cell (CD4) count below 350 cell/l, but the implementation of this is limited due to availability of medication. However, cART initiation at higher CD4 count increases survival, albeit at higher lifetime treatment cost. This analysis evaluates the cost-effectiveness of initiating cART at a CD4 count between 250-350 cell/l (early) versus

Original languageEnglish (US)
Article number736
JournalBMC Public Health
Volume12
Issue number1
DOIs
StatePublished - 2012

Fingerprint

Uganda
CD4 Lymphocyte Count
Cost-Benefit Analysis
Health Care Costs
Therapeutics
Cell Count
Guidelines
T-Lymphocytes

Keywords

  • Adverse effects
  • Economics
  • HAART
  • Mortality

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda. / Sempa, Joseph; Ssennono, Mark; Kuznik, Andreas; Lamorde, Mohammed; Sowinski, Stefanie; Semeere, Aggrey; Hermans, Sabine; Castelnuovo, Barbara; Manabe, Yukari C.

In: BMC Public Health, Vol. 12, No. 1, 736, 2012.

Research output: Contribution to journalArticle

Sempa, J, Ssennono, M, Kuznik, A, Lamorde, M, Sowinski, S, Semeere, A, Hermans, S, Castelnuovo, B & Manabe, YC 2012, 'Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda', BMC Public Health, vol. 12, no. 1, 736. https://doi.org/10.1186/1471-2458-12-736
Sempa, Joseph ; Ssennono, Mark ; Kuznik, Andreas ; Lamorde, Mohammed ; Sowinski, Stefanie ; Semeere, Aggrey ; Hermans, Sabine ; Castelnuovo, Barbara ; Manabe, Yukari C. / Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda. In: BMC Public Health. 2012 ; Vol. 12, No. 1.
@article{547803158d7d406588855f8fdb8972bc,
title = "Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda",
abstract = "Background: Ugandan national guidelines recommend initiation of combination antiretroviral therapy (cART) at CD4 + T cell (CD4) count below 350 cell/l, but the implementation of this is limited due to availability of medication. However, cART initiation at higher CD4 count increases survival, albeit at higher lifetime treatment cost. This analysis evaluates the cost-effectiveness of initiating cART at a CD4 count between 250-350 cell/l (early) versus",
keywords = "Adverse effects, Economics, HAART, Mortality",
author = "Joseph Sempa and Mark Ssennono and Andreas Kuznik and Mohammed Lamorde and Stefanie Sowinski and Aggrey Semeere and Sabine Hermans and Barbara Castelnuovo and Manabe, {Yukari C}",
year = "2012",
doi = "10.1186/1471-2458-12-736",
language = "English (US)",
volume = "12",
journal = "BMC Public Health",
issn = "1471-2458",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda

AU - Sempa, Joseph

AU - Ssennono, Mark

AU - Kuznik, Andreas

AU - Lamorde, Mohammed

AU - Sowinski, Stefanie

AU - Semeere, Aggrey

AU - Hermans, Sabine

AU - Castelnuovo, Barbara

AU - Manabe, Yukari C

PY - 2012

Y1 - 2012

N2 - Background: Ugandan national guidelines recommend initiation of combination antiretroviral therapy (cART) at CD4 + T cell (CD4) count below 350 cell/l, but the implementation of this is limited due to availability of medication. However, cART initiation at higher CD4 count increases survival, albeit at higher lifetime treatment cost. This analysis evaluates the cost-effectiveness of initiating cART at a CD4 count between 250-350 cell/l (early) versus

AB - Background: Ugandan national guidelines recommend initiation of combination antiretroviral therapy (cART) at CD4 + T cell (CD4) count below 350 cell/l, but the implementation of this is limited due to availability of medication. However, cART initiation at higher CD4 count increases survival, albeit at higher lifetime treatment cost. This analysis evaluates the cost-effectiveness of initiating cART at a CD4 count between 250-350 cell/l (early) versus

KW - Adverse effects

KW - Economics

KW - HAART

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=84868615891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868615891&partnerID=8YFLogxK

U2 - 10.1186/1471-2458-12-736

DO - 10.1186/1471-2458-12-736

M3 - Article

C2 - 22943068

AN - SCOPUS:84868615891

VL - 12

JO - BMC Public Health

JF - BMC Public Health

SN - 1471-2458

IS - 1

M1 - 736

ER -